Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 10, 2013, Pages 1757-1770

  Karabudak, Aykan A ^a   Hafner, Julie ^a   Shetty, Vivekananda ^a   Chen, Songming ^c   Secord, Angeles Alvarez ^b   Morse, Michael A ^b   Philip, Ramila ^a  

^a Immunotope Inc   (United States)

^b DUKE UNIVERSITY   (United States)

^c Institute for Hepatitis and Virus Research   (United States)

Author keywords

Autoantibodies; Biomarkers; Dot blot; iTRAQ; Microarray; Proteomics

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CA 125 ANTIGEN; RECOMBINANT AUTOANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DOT HYBRIDIZATION; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADENOCARCINOMA; AGED; ANTIBODIES, NEOPLASM; AUTOANTIBODIES; AUTOANTIGENS; CA-125 ANTIGEN; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84884675803     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1501-6     Document Type: Article

References (69)

1. Abendstein B, Marth C, Muller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG (2000) Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 88(6):1432-1437
2. Aggarwal K, Choe LH, Lee KH (2005) Quantitative analysis of protein expression using amine-specific isobaric tags in Escherichia coli cells expressing rhsA elements. Proteomics 5(9):2297-2308
3. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1(11):845-867
4. Anderson KS, LaBaer J (2005) The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 4(4):1123-1133
5. Blaes F, Klotz M, Huwer H, Straub U, Kalweit G, Schimrigk K, Schafers HJ (2000) Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg 69(1):254-258
6. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM (2001) An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 98(17):9824-9829
7. Burnham TK (1972) Antinuclear antibodies in patients with malignancies. Lancet 2(7774):436
8. Caiazzo RJ Jr, O'Rourke DJ, Barder TJ, Nelson BP, Liu BC (2011) Native antigen fractionation protein microarrays for biomarker discovery. Methods Mol Biol (Clifton, NJ) 723:129-148
9. Canelle L, Bousquet J, Pionneau C, Deneux L, Imam-Sghiouar N, Caron M, Joubert-Caron R (2005) An efficient proteomics-based approach for the screening of autoantibodies. J Immunol Methods 299(1-2):77-89. doi: 10.1016/j.jim.2005.01. 015
10. Caron M, Choquet-Kastylevsky G, Joubert-Caron R (2007) Cancer Immunomics Using Autoantibody Signatures for Biomarker Discovery. Mol Cell Proteomics 6(7):1115-1122
11. Chaib H, Rubin MA, Mucci NR, Li L, Taylor JMG, Day ML, Rhim JS, Macoska JA (2001) Activated in prostate cancer: a PDZ domain-containing protein highly expressed in human primary prostate tumors. Cancer Res 61(6):2390-2394
12. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA (2006) Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 66(2):1181-1190
13. Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, Brand RE, Haab BB (2007) Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 4(5):437-444. doi: 10.1038/nmeth1035
14. Chen Z, Fadiel A, Feng Y, Ohtani K, Rutherford T, Naftolin F (2001) Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor. Cancer 92(12):3068-3075
15. Ehrlich JR, Qin S, Liu BC (2006) The 'reverse capture' autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 1(1):452-460
16. Ferrini R (1997) Screening asymptomatic women for ovarian cancer: American College of Preventive Medicine practice policy. Am J Prev Med 13(6):444-446
17. Fossa A, Alsoe L, Crameri R, Funderud S, Gaudernack G, Smeland EB (2004) Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 53(5):431-438
18. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC (2008) Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res 14(3):764-771
19. Gautreau A, Louvard D, Arpin M (2002) ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol 14(1):104-109
20. Gercel-Taylor C, Bazzett LB, Taylor DD (2001) Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol Oncol 81(1):71-76
21. Gure AO, Altorki NK, Stockert E, Scanlan MJ, Old LJ, Chen YT (1998) Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. Cancer Res 58(5):1034-1041
22. Haab BB (2005) Antibody arrays in cancer research. Mol Cell Proteomics 4(4):377-383
23. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70
24. Hays JL, Kim G, Giuroiu I, Kohn EC (2010) Proteomics and ovarian cancer: integrating proteomics information into clinical care. J Proteomics 73(10):1864-1872
25. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M (2000) Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 161(2 Pt 1):589-594
26. Hotulainen P, Paunola E, Vartiainen MK, Lappalainen P (2005) Actin-depolymerizing factor and cofilin-1 play overlapping roles in promoting rapid F-actin depolymerization in mammalian nonmuscle cells. Mol Biol Cell 16(2):649-664
27. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187(2):265-270
28. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60(5):277-300
29. Le Naour F, Brichory F, Misek DE, Brechot C, Hanash SM, Beretta L (2002) A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 1(3):197-203
30. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88(3):323-331
31. Li M, Yin J, Mao N, Pan L (2013) Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo. Oncol Rep 29(1):58-66
32. Luborsky JL, Barua A, Shatavi SV, Kebede T, Abramowicz J, Rotmensch J (2005) Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol 54(2):55-62
33. Luo LY, Herrera I, Soosaipillai A, Diamandis EP (2002) Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. Br J Cancer 87(3):339-343
34. Maddison P, Newsom-Davis J, Mills KR, Souhami RL (1999) Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353(9147):117-118
35. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102(21):7677-7682
36. Mueller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Buchler M, Beger HG, Vila MR, Adler G, Gress TM (1997) Cloning of a gene highly over-expressed in cancer coding for a novel KH-domain containing protein. Oncogene 14(22):2729-2733
37. Naora H, Montz FJ, Chai CY, Roden RB (2001) Aberrant expression of homeobox gene HOXA7 is associated with mullerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. Proc Natl Acad Sci USA 98(26):15209-15214
38. Nesterova M, Johnson N, Cheadle C, Cho-Chung YS (2006) Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 1762(4):398-403
39. Nishimura S, Tsuda H, Kataoka F, Arao T, Nomura H, Chiyoda T, Susumu N, Nishio K, Aoki D (2011) Over-expression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy. Hum Pathol 42(4):516-521
40. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R (2008) The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 199(3):215-223
41. Ohtani K, Sakamoto H, Rutherford T, Chen Z, Satoh K, Naftolin F (1999) Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett 147(1-2):31-38
42. Old LJ, Chen YT (1998) New paths in human cancer serology. J Exp Med 187(8):1163-1167
43. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS (2009) Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 113(4):775-782
44. Piver MS, Wong C (1998) Role of prophylactic surgery for women with genetic predisposition to cancer. Clin Obstet Gynecol 41(1):215-224
45. Polesello C, Delon I, Valenti P, Ferrer P, Payre F (2002) Dmoesin controls actin-based cell shape and polarity during Drosophila melanogaster oogenesis. Nat Cell Biol 4(10):782-789
46. Robinson C, Callow M, Stevenson S, Scott B, Robinson BW, Lake RA (2000) Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J Respir Cell Mol Biol 22(5):550-556
47. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr (2005) Potential markers that complement expression of CA-125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-277
48. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3(12):1154-1169
49. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92(25):11810-11813
50. Sasaroli DCG, Scholler N (2009) Beyond CA-125: the coming of age of ovarian cancer biomarkers. Are we there yet? Biomark Med 3:275-288
51. Shetty V, Hafner J, Shah P, Nickens Z, Philip R (2012) Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. Clin Proteomics 9(1):10
52. Song J, Fadiel A, Edusa V, Chen Z, So J, Sakamoto H, Fishman DA, Naftolin F (2005) Estradiol-induced ezrin over-expression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett 220(1):57-65
53. Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60(7):1777-1788
54. Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H (2004) Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. J Urol 171(1):182-186
55. Tan EM (1991) Autoantibodies in pathology and cell biology. Cell 67(5):841-842
56. Tan EM, Chan EK, Sullivan KF, Rubin RL (1988) Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol 47(2):121-141
57. Taylor DD, Gercel-Taylor C (1998) Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? (review). Oncol Rep 5(6):1519-1524
58. Taylor DD, Gercel-Taylor C, Parker LP (2009) Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 115(1):112-120
59. Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9(4):138-141
60. Vogl FD, Stickeler E, Weyermann M, Kohler T, Grill HJ, Negri G, Kreienberg R, Runnebaum IB (1999) p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology 57(4):324-329
61. Vogl FD, Frey M, Kreienberg R, Runnebaum IB (2000) Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 83(10):1338-1343
62. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO, Hilgers J (2000) Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 86(5):702-712
63. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353(12):1224-1235
64. Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, Symons M, Segall J, Eddy R, Miki H, Takenawa T, Condeelis J (2005) Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol 168(3):441-452
65. Yamamoto A, Shimizu E, Ogura T, Sone S (1996) Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int J Cancer 69(4):283-289
66. Yap CT, Simpson TI, Pratt T, Price DJ, Maciver SK (2005) The motility of glioblastoma tumour cells is modulated by intracellular cofilin expression in a concentration-dependent manner. Cell Motil Cytoskelet 60(3):153-165
67. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM (2003) Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12(2):136-143
68. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64(16):5882-5890
69. Zhu B, Fukada K, Zhu H, Kyprianou N (2006) Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. Cancer Res 66(17):8640-8647